Uniqure is a biotechnology business based in the US. Uniqure shares (QURE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.70 – a decrease of 3.52% over the previous week. Uniqure employs 209 staff and has a trailing 12-month revenue of around $27.1 million.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – QURE.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Uniqure stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Uniqure stock price (NASDAQ: QURE)
Use our graph to track the performance of QURE stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Uniqure price performance over time
Historical closes compared with the close of $13.93 from 2025-03-20
1 week (2025-03-14)
-1.90%
1 month (2025-02-21)
8.49%
3 months (2024-12-20)
-17.96%
6 months (2024-09-20)
159.89%
1 year (2024-03-22)
163.83%
2 years (2023-03-22)
-25.51%
3 years (2022-03-22)
17.74
5 years (2020-03-20)
43.12
Uniqure financials
Revenue TTM
$27.1 million
Gross profit TTM
$-132,840,000
Return on assets TTM
-16.39%
Return on equity TTM
-238.46%
Profit margin
0%
Book value
$-0.14
Market Capitalization
$767.9 million
TTM: trailing 12 months
Uniqure share dividends
We're not expecting Uniqure to pay a dividend over the next 12 months.
Have Uniqure's shares ever split?
Uniqure's shares were
split on a 1:5 basis on 30 January 2014
. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Uniqure shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Uniqure shares which in turn could have impacted Uniqure's share price.
Uniqure share price volatility
Over the last 12 months, Uniqure's shares have ranged in value from as little as $3.73 up to $19.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Uniqure's is 0.363. This would suggest that Uniqure's shares are less volatile than average (for this exchange).
Uniqure overview
uniQure N. V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Frequently asked questions
What percentage of Uniqure is owned by insiders or institutions? Currently 8.593% of Uniqure shares are held by insiders and 77.636% by institutions.How many people work for Uniqure? Latest data suggests 209 work at Uniqure.When does the fiscal year end for Uniqure? Uniqure's fiscal year ends in December.Where is Uniqure based? Uniqure's address is: Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BPWhat is Uniqure's ISIN number? Uniqure's international securities identification number is: NL0010696654What is Uniqure's CUSIP number? Uniqure's Committee on Uniform Securities Identification Procedures number is: N90064101
Check out the best-performing ETFs so far in 2025.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
